Skip to main content

Table 4 Multivariable analyses of PFS and OS (Model 1)

From: Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy

Variables PFS OS
HR 95% CI p value HR 95% CI p value
Age (years)    0.443    0.973
  ≤ 65 Ref.    Ref.   
 >65 1.177 0.776–1.787   0.992 0.634–1.553  
ECOG PS    0.443    0.350
 0 Ref.    Ref.   
 1 1.164 0.790–1.714   1.214 0.808–1.823  
Clinical stage    0.003**    0.002**
 IIIB Ref.    Ref.   
 IV 1.807 1.229–2.658   1.880 1.260–2.806  
First-line response    0.037*    0.011*
 CR/PR Ref.    Ref.   
 SD/PD 1.572 1.027–2.407   1.799 1.143–2.831  
Albumin    0.089    
 Decreased 1.377 0.952–1.991     
 Normal Ref.      
LMR    0.025*    0.032*
  ≤ 3.73 1.602 1.060–2.420   1.621 1.042–2.521  
 >3.73 Ref.    Ref.   
SUVmax    < 0.001***    < 0.001***
  ≤ 11.6 Ref.    Ref.   
 >11.6 2.110 1.400–3.179   2.760 1.789–4.257  
  1. PFS progression-free survival, OS overall survival, ECOG PS Eastern Cooperative Oncology Group Performance Status, CR complete response, PR partial response, SD stable disease, PD progressive disease, LMR lymphocyte-monocyte ratio, SUVmax maximum standardized uptake value, HR hazard ratio, CI confidence intervals. *, p < 0.05; **, p < 0.01; ***, p < 0.001